Agora Open Science Trust

What Agora Open Science Trust does

Agora Open Science Trust is a federally incorporated Canadian non-share not-for-profit corporation and registered charity (Charitable Registration #81485 1960 RR0001), headquartered at MaRS South Tower, 101 College Street, Suite 700, Toronto, Ontario. The organization operates three program pillars — Affordable Medicines, Reproducibility in Biomedicine, and Policy and Advocacy — aimed at developing affordable new medicines for rare and neglected diseases that traditional pharmaceutical development models have ignored due to limited commercial returns. All research outputs are released under CC-BY 4.0, making data, methods, and findings freely available to the global scientific community.

The organization's core technology stack is an open-science drug discovery workflow combining AI-driven compound design with synthetic chemistry execution. Its first documented therapeutic project targets PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), conducted in partnership with Enamine (synthetic chemistry) and Variational AI (AI-driven design). Rather than building proprietary infrastructure in-house, Agora coordinates external contributors and applies open-science principles — transparency, rapid iteration, and shared data — to accelerate early-stage discovery in diseases where commercial incentives are weak.

Agora does not sell commercial products or services and operates no pricing model. Revenue is generated exclusively through donations and charitable contributions, supplemented by in-kind contributions from research partners. Go-to-market is community-led: the organization engages researchers and donors globally through its website, direct email outreach, advocacy initiatives, and event-driven partnerships around specific drug discovery targets. With a 1-10 employee team, execution is partner-leveraged, and the organization's role is closer to an orchestrator and steward of open R&D than to a vertically integrated drug developer.

Name

Agora Open Science Trust

Legal name

AGORA OPEN SCIENCE TRUST

Website

https://agoraopensciencetrust.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Agora Open Science Trust is a Canadian nonprofit charity that runs open-science drug discovery, reproducibility, and policy advocacy programs to develop affordable medicines for rare and neglected diseases, coordinating external research and AI-design partners under CC-BY 4.0 licensing.

Ownership category

akta.pro rank

Product category

Non-Profit Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Open science drug discovery
• Affordable medicines development
• Biomedical research charity
• Drug discovery programs
• Policy advocacy health

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Donations and Charitable Contributions: As a Canadian registered charity (Registration #81485 1960 RR0001), Agora Open Science Trust operates primarily through donations from individuals, organizations, and funding partners who support their mission of creating affordable medicines through open science.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Agora Open Science Trust is a Canadian charitable non-profit that conducts enabling research, targeted drug discovery and development projects, and policy advocacy aimed at bringing affordable new medicines to patients through open science. It carries out programs in Affordable Medicines, Reproducibility in Biomedicine, and Policy and Advocacy, and collaborates with international research partners (e.g., Enamine, Variational AI) on specific drug discovery projects such as PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy.

Product overview

Agora Open Science Trust is a Canadian charitable organization (non-profit corporation) focused on open science drug discovery and development. The organization does not offer commercial products or services in the traditional sense. Instead, it carries out enabling research, targeted drug discovery projects, and policy advocacy aimed at bringing affordable new medicines to patients through open science principles. The organization's programs include Affordable Medicines, Reproducibility in Biomedicine, and Policy and Advocacy initiatives. They collaborate with international research partners on specific drug discovery projects, such as the PRMT6 inhibitor project conducted with Enamine and Variational AI for Spinal and Bulbar Muscular Atrophy (SBMA) treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Affordable Medicines Program
• Reproducibility in Biomedicine Program Enabling research program focused on promoting transparency, reproducibility, and open science methodologies in biomedical research to strengthen the reliability of scientific findings. Targeted at the global research community and patients who depend on reproducible biomedical science.
• Policy and Advocacy Program Policy advocacy program aimed at promoting open science as a model for creating affordable medicines and advancing systemic reforms in drug development and access. Targeted at policymakers, regulators, and the broader public.

Quantifiable outcome

• Open science model enables transparency and rapid iteration in early discovery stages

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• EnaminecoreStrategic or Co-development Partner · 24 March 2026Enamine collaborated with Agora Open Science Trust and Variational AI to discover novel PRMT6 inhibitors aimed at treating Spinal and Bulbar Muscular Atrophy (SBMA). The project utilizes Enamine's synthetic chemistry capabilities combined with AI-driven design and open science principles to accelerate drug discovery.
• Variational AIcoreStrategic or Co-development Partner · 24 March 2026Variational AI partnered with Agora Open Science Trust and Enamine to apply AI-driven design methodologies for developing novel PRMT6 inhibitors for SBMA treatment. The collaboration emphasizes transparency and rapid iteration in early discovery stages.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Wellcome Trust: Major charitable foundation funding health research including drug discovery for neglected diseases. Comparable as a health research grantmaker, though a funder rather than an in-house discovery operator.
• TB Alliance: Nonprofit developing faster, affordable TB regimens and coordinating global TB drug R&D. Comparable as a mature nonprofit drug-development organization focused on affordability and access.
• Bill & Melinda Gates Foundation (Global Health): Largest philanthropic funder of global health R&D, including drug discovery for diseases of poverty. Comparable as a major nonprofit funder in the same neglected-disease space where Agora operates.
• Medicines for Malaria Venture (MMV): Established nonprofit product development partnership for antimalarial drug R&D. Broader incumbent in the nonprofit drug-discovery space with similar funding mechanics and neglected-disease focus.

Emerging players

• Every Cure: Nonprofit focused on drug repurposing to treat neglected and rare diseases. Similar mission (affordable access, underserved patients) with an adjacent (repositioning) strategy to Agora's de novo discovery.
• Critical Path Institute: Nonprofit collaborating with regulators, academia, and industry to accelerate drug development through data sharing and consortia. Adjacent nonprofit drug-development partner with shared emphasis on collaboration and reproducibility.
• Sage Bionetworks: Nonprofit driving open, collaborative biomedical research and data sharing. Strong methodological peer around open-science principles and reproducibility, though differentiated from small-molecule discovery.

Direct peers

• Drugs for Neglected Diseases initiative (DNDi): International nonprofit drug R&D organization that develops treatments for neglected patients and diseases. Most direct functional peer to Agora: nonprofit-funded, mission-driven drug discovery for diseases underserved by commercial pharma.
• Open Source Malaria: Open-science consortium developing new antimalarial drugs through openly shared data and methods. Direct model peer: nonprofit, open-IP drug discovery for a neglected-disease target.
• Open Source Pharma Foundation: Nonprofit promoting open and collaborative approaches to pharmaceutical research and affordable medicines. Closest philosophical and methodological peer, sharing the open-science, affordability-first charter.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/agoraopensci
• LinkedInlinkedin.com/company/agora-open-science-trust

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agora Open Science Trust